CAM
EWTX icon

Cormorant Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Cormorant Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103M Sell
3,260,000
-25,000
-0.8% -$721K 5.16% 4
2025
Q4 		$81.5M Sell
3,285,000
-725,000
-18% -$14.6M 3.77% 11
2025
Q3 		$65M Sell
4,010,000
-241,992
-6% -$3.43M 4.49% 6
2025
Q2 		$55.7M Buy
4,251,992
+150,000
+4% +$2.16M 4.15% 6
2025
Q1 		$90.2M Buy
4,101,992
+695,458
+20% +$18.2M 6.79% 2
2024
Q4 		$91M Hold
3,406,534
– – 5% 5
2024
Q3 		$90.9M Buy
3,406,534
+400,000
+13% +$7.96M 4.82% 5
2024
Q2 		$54.1M Hold
3,006,534
– – 3.13% 9
2024
Q1 		$54.8M Buy
3,006,534
+454,545
+18% +$7.22M 2.41% 10
2023
Q4 		$27.9M Sell
2,551,989
-394,898
-13% -$2.77M 1.33% 21
2023
Q3 		$16.9M Hold
2,946,887
– – 0.99% 25
2023
Q2 		$22.8M Hold
2,946,887
– – 1.28% 24
2023
Q1 		$19.7M Hold
2,946,887
– – 1.29% 21
2022
Q4 		$26.3M Sell
2,946,887
-105,102
-3% -$985K 1.76% 17
2022
Q3 		$30M Sell
3,051,989
-798,011
-21% -$8.06M 2.1% 17
2022
Q2 		$30.6M Sell
3,850,000
-832,874
-18% -$6.3M 2.32% 12
2022
Q1 		$45.4M Buy
4,682,874
+1,116,973
+31% +$14.4M 3.49% 8
2021
Q4 		$54.5M Buy
3,565,901
+194,987
+6% +$3.51M 3.24% 8
2021
Q3 		$56M Buy
3,370,914
+230,000
+7% +$4.16M 2.27% 12
2021
Q2 		$66.5M Buy
3,140,914
+800,000
+34% +$21.9M 2.26% 12
2021
Q1 		$74.3M Buy
+2,340,914
New +$75.9M 1.66% 14

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cormorant Asset Management's EWTX Position: Q1 2026 in Review

Cormorant Asset Management reduced its Edgewise Therapeutics (EWTX) stake by 0.76% in Q1 2026, selling an estimated $721K and leaving 3,260,000 shares worth $103M. The position accounts for 5.16% of the portfolio, ranked #4.

Cormorant Asset Management first reported a position in EWTX in Q1 2021 and has held it in 21 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Cormorant Asset Management held 3,260,000 shares of Edgewise Therapeutics worth $103M as of Q1 2026.
  • Cormorant Asset Management sold 25,000 Edgewise Therapeutics shares in Q1 2026, an estimated $721K.
  • Edgewise Therapeutics made up 5.16% of Cormorant Asset Management's portfolio in Q1 2026, its #4 holding.
  • Cormorant Asset Management first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.